StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)

Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%

Castle Biosciences enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Castle Biosciences's enterprise value was $780.26M on Nov 11, 2026, against $887.52M a year earlier. Over the last 5 years it ranged from $134.08M to $887.52M, with a median of $412.43M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$780.26M-8.9%
2025Dec 31, 2025$856.90M+80.1%
2024Dec 31, 2024$475.79M+35.7%
2023Dec 29, 2023$350.54M-1.1%
2022Dec 30, 2022$354.31M-50.8%
2021Dec 31, 2021$720.86M-38.5%
2020Dec 31, 2020$1.17B+126.6%
2019Dec 31, 2019$517.26M–

More Castle Biosciences figures

See a number that looks wrong?